Login to Your Account

Pfizer Picking Up FoldRx in Latest Rare Disease Buyout

By Jennifer Boggs

Thursday, September 2, 2010
Just days after Sanofi-Aventis SA's official bid for Genzyme Corp., big pharma's pursuit of orphan drugs continued with Pfizer Inc.'s plan to buy out privately held FoldRx Pharmaceuticals Inc. for rights to a drug for rare neurodegenerative disease transthyretin amyloid polyneuropathy (ATTR-PN). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription